An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
This article was originally published in The Pink Sheet Daily
Executive Summary
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.